skip to content
Detailed Quote
5i Report

Review of Cipher Pharmaceuticals

AUG 16, 2018 - Dermatology pharmaceutical business with recent acquisition and growth in product pipeline, with some mixed results in the past. Coverage dropped until some visibility emerges.

Download Report
Company Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: Going to do a little re-balancing and the result will be the addition of one new { possibly two depending on your answer } stocks to the portfolio ...... Between ISRG, CPH, GLXY, and MDA please rank from first choice to last giving each a numerical score between one and ten with ten being best . This will allow me to evaluate how much you like one better than the other ......Also a short blurb on each explaining why ......Thanks for your terrific service Garth ......
Read Answer Asked by Garth on October 30, 2024
Q: Just finished reading both questions and your report on CPH ..... I don't see any resemblance between your report and the current company .... Could you give me the " Cole's Notes " review of the state of the current company ? What's positive in the pipeline ? What's negative ? I see the failure of the nail fungus drug initially dropped the stock $5 but it has recovered since. Does that mean the drug is not dead ? Thanks for your terrific service ..... { any plans to update that report ? }
Read Answer Asked by Garth on October 17, 2024
Insiders
Share Information
News and Media